Skip to content
OpenCapital
Get started

Palvella Therapeutics PVLA Q1 2026 Annual earnings

Reported May 7, 2026 · Before market open

EPS-$1.20Miss by $0.30
EPS estimate-$0.90

Next report

Aug 13, 2026 (In 2 weeks)
EPS estimate-$1.16

Financials

Q1 2026

Income statement

See full
Operating income-$14.9M-88.7%
Net income-$15.8M-92.6%
EPS (diluted)-$1.20-62.2%

Balance sheet

See full
Cash & equivalents$206.4M+173%
Total debt$584.0K—
Total equity$232.3M+318%
Total assets$263.8M+232%

Cash flow

See full
Operating cash flow-$10.9M-60.5%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$2.03B+361%
Enterprise value$1.83B—

Returns & leverage

See full
Return on equity-34.2%—
Debt / equity0×—
Current ratio28.9×+20.0×

Versus estimates

Diluted EPS

Q1 2026-$1.20Miss by $0.30
Q4 2025-$1.08Miss by $0.17Q3 2025-$1.03Miss by $0.18Q2 2025-$0.86Miss by $0.08Q1 2025-$0.74Beat by $2.66Q4 2024$4.00Beat by $4.39

Ask the moment Palvella Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Palvella Therapeutics report Q1 2026 earnings?
Palvella Therapeutics (PVLA) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Palvella Therapeutics's Q1 2026 revenue and EPS?
Palvella Therapeutics reported eps of $-1.20 for Q1 2026.
Did Palvella Therapeutics beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.90 by $0.30.
How did Palvella Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 62.2% from $-0.74.
Where can I find Palvella Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-210605) and the 10-K periodic report (0001193125-26-133372) directly on SEC EDGAR. The filing index links above go to sec.gov.